The maverick practice of off-label prescribing - giving drugs for unapproved conditions/patients - is once again in the limelight. The US Food and Drug Administration (FDA) has issued a warning against using ‘atypical antipsychotics’ to treat...
Crestor (rosuvastatin): The US Food and Drug Administration (FDA) has issued a Public Health Advisory notifying healthcare professionals that 22 members of the European Union (EU) have modified their labels for this drug
Drug companies have been accused of suppressing vital data showing that their new-generation atypical antipsychotics are killing around one in four elderly dementia patients. The startling discovery was made in nine separate studies that were...